国际病理科学与临床杂志    2010 30 (1): 8-   ISSN: 1673-2588  CN: 43-1458/R   不同剂量阿托伐他汀和停服后对肥胖高胆固醇血症患者 血管内皮功能和炎症因子的影响 马琦琳， 张赛丹， 黄澄， 蒋元军， 孙明， 杨天山仑 中南大学湘雅医院心内科， 长沙 410008 收稿日期 2009-10-20  修回日期 2009-12-30  网络版发布日期 null 参考文献  ［1］卫生部心血管病防治研究中心. 2005年中国心血管病报告［M］. 北京: 中国大百科全书出版社, 2006: 14. The National Centre for Cardiovascular Disease Control & Research. Chinese Cardiovascular Disease Report 2005［M］.Beijing: Encyclopedia of China Publishing House, 2006: 14. ［2］李向平，李江，赵水平,等.血管内皮依赖性舒张功能的无创性检测［J］. 湖南医科大学学报, 1997，22（5）：387389. LI Xiangping, LI Jiang, ZHAO Shuiping, et al. A noninvasive method for detecting endothelium dependent dilation ［J］.Bulletin of Huan Medical University, 1997，22（5）:387389. ［3］Klein S, Allison DB, Heymsfield SB, et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America’s Health［J］. Am J Clin Nutr, 2007, 85(5): 11971202. ［4］Eckel RH, York DA, Rossner S, et al. Prevention conference Ⅶ: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary［J］. Circulation, 2004, 110(7): 29682975. ［5］Meisinger C, Doring A, Thorand B, et al. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study ［J］. Am J Clin Nutr, 2006, 84(3): 483489. ［6］刘静, 赵冬, 吴兆苏,等. 低密度脂蛋白胆固醇与心血管病发病关系的前瞻性研究［J］. 中华心血管病杂志, 2001, 29(9): 561565. LIU Jing, ZHAO Dong, WU Zhaosu, et al. Association of low density lipoprotein cholesterol with cardiovascular disease in a prospective study ［J］. Chinese Journal of Cardiology, 2001, 29(9): 561565. ［7］李莹, 陈志红, 周北凡,等. 血脂和脂蛋白水平对我国中年人群缺血性心血管病事件的预测作用［J］. 中华心血管病杂志, 2004, 32(7): 643647. LI Ying, CHEN Zhihong, ZHOU Beifan, et al. The predictive effects of lipids and lipoproteins on the incidence of ischemic cardiovascular disease in middle aged Chinese population ［J］. Chinese Journal of Cardiology, 2004, 32(7): 643647. ［8］Ito MK, Talbert RL, Tsimikas S. Statinassociated pleiotropy: possible neneficial effects beyond cholesterol reduction ［J］. Pharmacotherapy, 2006, 26(7Pt2): 85s97s. ［9］Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrastinduced nephropathy and to improve longterm outcome in patients undergoing percutaneous coronany intervention ［J］. Am J Cardiol, 2008, 101(3): 279285. ［10］Ichiki T, Takeda K, Tokunou T, et al. Downregulation of angiotensin Ⅱ type 1 receptor by hydrophobic 3hydroxy3methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells ［J］. Arterioscler Thromb Vasc Biol, 2001, 21(12): 18961901. ［11］Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery ［J］. Eur J Cardiothorac Surg, 2005, 28(6): 805810. ［12］Mason JC, Ahmed Z, Mankoff R, et al. Statininduced expression of decayaccelerating factor protects vascular endothelial against complementmediated injury ［J］. Circ Res, 2002, 91(8): 696703. ［13］夏尊恩，李艳，汪明,等. 阿托伐他汀经ERK信号转导通路抑制CD40L诱导的内皮细胞E选择素的表达［J］. 中华医学杂志，2008, 12(48): 34323435. XIA Zunen, LI Yan, WANG Ming, et al. Inhibitor of CD40L induced Eselectin expression in endothelial cells through extracellular signalregulated kinase signaling pathway ［J］. National Medical Journal of China, 2008, 12(48): 34323435. ［14］Bonnet J, Mcpherson R, Tedgni A, et al. Comparative effects of 10mg versus 80mg atorvastatin on highsensitivity Creactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study ［J］. Clin Ther, 2008, 30(12): 22982313. 通讯作者: 马琦琳